Study tracks stem cell transplant outcomes for severe sclerosis
An international study reports long-term survival benefits and safety risks for patients receiving stem cell transplants for severe systemic sclerosis.
Researchers followed eighty patients for nine years after they received autologous bone marrow transplants to treat their early severe autoimmune disease conditions. The data shows sustained disease control while highlighting specific long-term risks that require careful clinical monitoring and expert oversight.
Estimated progression-free survival reached 60% at ten years, while overall survival remained at 71% across the entire international cohort. Many patients remained alive without needing further immunosuppressive treatment, indicating durable disease control following the initial aggressive medical intervention procedures.
Skin scores improved significantly over time, dropping from twenty-four at baseline to just five at the ten-year mark of the study. Lung capacity measurements also stayed relatively stable, showing that vital organ function was preserved during this extended period of observation and care.
Eighteen deaths occurred during the follow-up period, with causes ranging from early transplant complications to disease progression and late infections. These findings emphasize the need for careful patient selection and structured long-term monitoring in experienced medical centers worldwide.
“These long-term findings help clinicians understand the durability of systemic sclerosis disease control following autologous HCT, while highlighting the risks that require continued monitoring.”